HP and non-autoimmune hemolytic anemia: Moreover, while haptoglobin is being explored as a therapeutic target in conditions such as haemolytic anaemias, sepsis, and cardiovascular diseases, there is still insufficient understanding of how specific modulation of haptoglobin activity could be leveraged to improve clinical outcomes.